Information sur le cancer / Types de cancer / Vessie / Traitement / Récidive

Alberta Health Services. (2013, October). Muscle Invasive and Locally Advanced/Metastatic Bladder Cancer Clinical Practice Guideline GU-002 (Version 5). Extrait de: https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu002-bladder.pdf.

Alberta Health Services. (2013, October). Nonmuscle Invasive Bladder Cancer Clinical Practice Guideline GU-009 (Version 1). Extrait de: https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu009-noninvasive-bladder.pdf.

American Cancer Society. (2016, January 26). Treating Bladder Cancer. Extrait de: https://www.cancer.org/cancer/bladder-cancer/treating.html.

American Society of Clinical Oncology. (2017, October). Bladder Cancer. Extrait de: https://www.cancer.net/cancer-types/bladder-cancer.

Cancer Care Ontario. (2017). Bladder Cancer Diagnosis, Treatment and Follow-up Care Pathway Map (Version 2017.02). Extrait de: http://ocp.cancercare.on.ca/cms/One.aspx?portalId=327895&pageId=370578.

Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline. (2017, September). Journal of Urology. 198(3):552-559. Extrait de: https://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasive-(2017).

Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. (2016, October). Journal of Urology. 196(4):1021-1029. Extrait de: https://www.auanet.org/guidelines/bladder-cancer-non-muscle-invasive-(2016).

Drugs and Health Products, Health Canada. (2017, September 9). Regulatory Decision Summary: Keytruda. Extrait de: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00286.

Drugs and Health Products, Health Canada. (2018, February 21). Summary Basis of Decision (SBD) for IMFINZI. Extrait de: https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00384.

Drugs and Health Products, Health Canada. (2018, May 31). Qualifying Notice: Bavencio. Extrait de: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/bavencio-208742-qualifying-notice.html.

Feldman AS, Efstathiou JA, Lee RJ, Dahl DM, Michaelson MD, Zietman AL. Cancer of the bladder, ureter, and renal pelvis. DeVita VT Jr, Lawrence TS, Rosenberg SA. (2015). Cancer: Principles and Practice of Oncology. (10th Édition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 65:896-916.

Finelli A, Brown J, Flood T, Kulkarni G, Hotte S, O’Malley M and the Genitourinary Cancer Advisory Committee, Cancer Care Ontario. (2018, January). Cancer Care Ontario Bladder Cancer Guideline 3-21: An Endorsement of the 2017 American Urological Association Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer - AUA, ASCO, ASTRO, SUO Guideline.

National Cancer Institute. (2018, April 12). Bladder Cancer Treatment (PDQ®) Health Professional Version. Extrait de: https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (Version 5.2018).

Penn Medicine. (2017, October 12). All About Bladder Cancer. University of Pennsylvania. Extrait de: https://www.oncolink.org/cancers/urinary-tract/bladder-cancer/all-about-bladder-cancer.